A Phase 3 interventional study of DFD-03 (0.1% tazarotene) Lotion and DFD-03 (0% tazarotene) Lotion (Placebo) in Acne Vulgaris, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2021-03-01.
Sponsored by Dr. Reddy's Laboratories Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing tazarotene in Acne Vulgaris — none open to participants now, none under way, none of them phase 3. tazarotene · Acne Vulgaris.
Among the 17 studies testing tazarotene in Acne Vulgaris, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 16th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →None of the 17 studies testing tazarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
tazarotene: first FDA approval 1997 (TAZORAC). What it is approved for, and how studies give it, is on its page →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 547 is above the median of 70 across 676 interventional studies indexed under Acne Vulgaris.
Median enrollment 210 across the 17 interventional studies. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 10 most frequent:
Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Dr. Reddy's Laboratories Limited has 4 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing tazarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Enrollment of subjects with mild to moderate facial acne vulgaris.
Co-Primary efficacy endpoints included:
Enrollment of subjects with mild to moderate facial acne vulgaris. Acne lesions of any severity on the chest and/or back (including shoulders) were enrolled provided they had mild to moderate acne on the face. During the 12-week treatment period subjects used the study product twice daily with approximately 12 hours between applications. Subjects were instructed to treat the entire face (and chest/back including shoulders, if applicable).
Co-Primary efficacy endpoints included:
The primary safety endpoint was treatment-emergent adverse events (TEAEs). Other safety variables included local cutaneous tolerance evaluation (dryness, non-lesional erythema, peeling, stinging, burning, and itching) and vital signs (blood pressure and pulse rate). Urine pregnancy tests were performed at Baseline and at every visit through Week 12 for all female subjects. A physical examination was performed at the Baseline Visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females, regardless of :
Must have a negative urine pregnancy test and if sexually active, must be on or use an acceptable method of birth control.
Exclusion Criteria:
Treatment with the following products:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DFD-03 Lotion (0.1% tazarotene)
Drug: DFD-03 (0.1% tazarotene) Lotion
DFD-03 Vehicle Lotion (0% tazarotene)
Drug: DFD-03 (0% tazarotene) Lotion (Placebo)
DFD-03 Lotion (0.1% tazarotene) - twice daily application
Also known as: DFD-03
DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
Also known as: Placebo
Absolute Change in the Inflammatory Lesion Counts on the Face
Change in inflammatory lesion counts on the face from baseline to Week 12
Time frame: Baseline to Week 12
Proportion of Subjects With a Clinical Response of "Success" at Week 12 for Lesions on the Face Based on IGA.
IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline)
Time frame: Baseline to Week 12
Absolute Change in the Non-inflammatory Lesion Counts on the Face
Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the ANCOVA model
Time frame: Baseline to Week 12
| Milestone | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) |
|---|---|---|
| Started | 275 | 272 |
| Completed | 214 | 230 |
| Not completed | 61 | 42 |
| Withdrew: Withdrawal by subject | 17 | 16 |
| Withdrew: Adverse event | 20 | 2 |
| Withdrew: Lost to follow-up | 24 | 24 |
Change in inflammatory lesion counts on the face from baseline to Week 12
| Lesions | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) |
|---|---|---|
| Baseline | 29.4 ± 13.82 | 29.7 ± 13.27 |
| Week 12 | 15.9 ± 12.14 | 18.2 ± 16.58 |
IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline)
| Participants | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) |
|---|---|---|
| Proportion of Subjects With a Clinical Response of "Success" at Week 12 for Lesions on the Face Based on IGA. | 58 | 26 |
Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the ANCOVA model
| Lesions | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) |
|---|---|---|
| Baseline | 44.8 ± 33.93 | 44.4 ± 27.75 |
| Week 12 | 24.3 ± 18.13 | 29.7 ± 23.12 |
Collected over Adverse event data were collected from the time treatment was initiated until study product treatment was discontinued (i.e. up to 12 weeks), except for spontaneously reported SAEs, which were to be reported up to 30 days after discontinuing study product use.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DFD-03 Lotion (0.1% Tazarotene) | 0/275 (0%) | 2/275 (0.7%) | 0/275 (0%) |
| DFD-03 Vehicle (0% Tazarotene) | 0/272 (0%) | 0/272 (0%) | 0/272 (0%) |
| Event | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) |
|---|---|---|
| Auto Accident with head traumaInjury, poisoning and procedural complications | 1/275 | 0/272 |
| Stomach UlcerGastrointestinal disorders | 1/275 | 0/272 |
| Age, Categorical(Participants) | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) | Total |
|---|---|---|---|
| <=18 years | 93 | 85 | 178 |
| Between 18 and 65 years | 182 | 187 | 369 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) | Total |
|---|---|---|---|
| Mean | 20.7 ± 6.5 | 21.3 ± 7.6 | 21.0 ± 7.1 |
| Sex: Female, Male(Participants) | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) | Total |
|---|---|---|---|
| Female | 143 | 111 | 254 |
| Male | 132 | 161 | 293 |
| Race (NIH/OMB)(Participants) | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 28 | 32 | 60 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 45 | 40 | 85 |
| White | 186 | 186 | 372 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 12 | 12 | 24 |
| Region of Enrollment(participants) | DFD-03 Lotion (0.1% Tazarotene) | DFD-03 Vehicle (0% Tazarotene) | Total |
|---|---|---|---|
| United States | 275 | 272 | 547 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in May 2018, 10 months.
Results were first posted in Jun 2020, 2 years after primary completion. A results delay was requested in Sep 2019.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 10 months is below that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tazarotene
Dr. Reddy's Laboratories Limited →